Categories Health Care, IPO

Two zero-revenue biotech stocks debut in a shaky IPO market

The IPO market has recently been pretty unwelcoming, with some of the popular firms going dud right after their debut. Endeavor Group Holdings and WeWork were sent scurrying back to review their IPO plans, primarily driven by the shifting investor tendency to ditch hype-driven firms. 

However, this was not a deterrent to two clinical-stage biotech firms that made their market debuts yesterday. It will be interesting to see how the market responds, especially given their small size and lack of product revenues.

stock market thanksgiving day black friday
Photo by Aditya Vyas on Unsplash

Frequency Therapeutics

The Woburn, Massachusetts-based firm aims at developing a treatment for sensorineural hearing loss (SNHL), which is the most common type of hearing loss. The disorder reportedly affects over 59 million people in the US alone.

The drug candidate – FX-322 – will begin Phase 2a clinical trial by the end of this year, results of which are expected by mid next 2020. Currently, SNHL does not have any FDA-approved drug therapies in the market. In the future, Frequency hopes to expand its proprietary approach, which it calls Progenitor Cell Activation, to other degenerative conditions such as multiple sclerosis.

frequency therapeutics net loss trend

On Thursday, the company floated 6 million shares for $14 apiece under the ticker FREQ, but the stock ended its first trading day down 2%.

READ: 4 biotech stocks that are ideal takeover targets

Aprea Therapeutics

Aprea Therapeutics is a more promising stock. It is an oncology-focused biopharmaceutical firm and its lead product candidate, APR-246 is currently undergoing Phase 3 trial. Notably, it has received orphan drug status from both the FDA and the European Medicines Agency for the treatment of myelodysplastic syndromes (MDS), a type of cancer.

Also Read:  Humana (HUM) can offer long-term returns despite high valuation

APR-246 also has a Fast Track designation from the FDA.

aprea therapeutics net loss trend

The company aims to treat cancer by reactivating mutant p53 tumor suppressor protein, which in its normal state functions to sense DNA damage and induce cell cycle arrest.

The company issued 5.7 million shares for $15 a share, and the stock ended its first trading day up at $20.50. The company, headquartered in Boston, is trading under the ticker APRE.  

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

COVID-19 drove retailers up the digital path years ahead than anticipated

Earlier we looked into how, during the COVID-19 pandemic, retailers saw changing trends in terms of their assortments and how the acceleration of online shopping led many of them to

Snowflake (SNOW) creates a record as the most successful software IPO ever; stock more than doubles

Data is at the heart of business innovation. Recognizing this trend, companies are seeking ways to transform their businesses by capturing, analyzing, and mobilizing data. The public cloud is becoming

Adobe (ADBE) sees new tailwinds as virtual shift gathers steam

The second half has been highly rewarding for design software maker Adobe Inc. (NASDAQ: ADBE) amid stable demand for digital content solutions. The company has remained unaffected by the virus-related

Top